New Affordable Diabetes and Heart Care Medicine Launched
India is home to a significant portion of the world’s diabetes population, with over 72 million people suffering from the condition. Furthermore, heart failure and kidney disease are common complications that often accompany diabetes. Until now, managing these conditions has been a significant challenge, especially for those from lower-income backgrounds due to the high cost of treatment. However, a new development in the pharmaceutical industry is set to change the game. Cadila Pharma has launched a new affordable medicine containing empagliflozin, a medication that not only controls blood sugar levels but also reduces heart risks, hospitalizations, and slows down kidney damage.
The new medicine, empagliflozin, is a type 2 diabetes treatment that has been widely used in the West. It has been shown to significantly reduce the risk of cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes. In addition, it has been found to slow down kidney damage and reduce the risk of hospitalization due to heart failure. Empagliflozin works by increasing the amount of glucose in the urine, which helps to lower blood sugar levels and reduce the risk of complications.
The significance of this new medicine lies in its affordability, making it accessible to a larger population. In India, where the cost of healthcare is a significant burden for many, this development is a welcome relief. The new medicine is priced lower than similar medications available in the market, making it an attractive option for patients who were previously unable to afford the treatment.
The launch of this medicine is a significant milestone in the fight against diabetes and its complications in India. Diabetes is a leading cause of morbidity and mortality in the country, and the complications that arise from it, such as heart failure and kidney disease, are a significant burden on the healthcare system. The new medicine offers a ray of hope for patients who were previously unable to access advanced treatment due to its high cost.
The benefits of empagliflozin are numerous. In addition to controlling blood sugar levels, it has been shown to:
- Reduce the risk of cardiovascular events, such as heart attacks and strokes
- Slow down kidney damage
- Reduce the risk of hospitalization due to heart failure
- Improve overall health outcomes
The launch of this medicine is a testament to the efforts of pharmaceutical companies like Cadila Pharma to make advanced treatments more accessible to patients. The company has been at the forefront of developing innovative medicines that address the needs of patients in India.
The availability of this medicine is a significant step forward in the fight against diabetes and its complications in India. With its long-term benefits and affordability, it is likely to make a significant impact on public health. The medicine is expected to be available at most pharmacies and hospitals across the country, making it easily accessible to patients.
In conclusion, the launch of empagliflozin, a new affordable medicine for diabetes, heart failure, and kidney disease, is a significant development in the Indian pharmaceutical industry. With its long-term benefits and affordability, it is likely to make a significant impact on public health. The medicine is a welcome relief for patients who were previously unable to access advanced treatment due to its high cost, and it is expected to improve overall health outcomes in the country.
Source: https://www.healthcareradius.in/features/pharma/cadila-pharma-diabetes
